Innate Pharma SA
PAR:IPH

Watchlist Manager
Innate Pharma SA Logo
Innate Pharma SA
PAR:IPH
Watchlist
Price: 1.668 EUR 1.46%
Market Cap: 153.8m EUR

Wall Street
Price Targets

IPH Price Targets Summary
Innate Pharma SA

Wall Street analysts forecast IPH stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for IPH is 4.995 EUR with a low forecast of 2.414 EUR and a high forecast of 6.51 EUR.

Lowest
Price Target
2.414 EUR
45% Upside
Average
Price Target
4.995 EUR
199% Upside
Highest
Price Target
6.51 EUR
290% Upside
Innate Pharma SA Competitors:
Price Targets
ALNY
Alnylam Pharmaceuticals Inc
20% Upside
PRQR
ProQR Therapeutics NV
316% Upside
301047
Sino Biological Inc
17% Upside
BNTX
BioNTech SE
46% Upside
ADAG
Adagene Inc
433% Upside
PHARM
Pharming Group NV
36% Upside
INSM
Insmed Inc
11% Upside
688177
Bio-Thera Solutions Ltd
58% Upside

Revenue
Forecast

Revenue Estimate
Innate Pharma SA

For the last 13 years the compound annual growth rate for Innate Pharma SA's revenue is 4%. The projected CAGR for the next 3 years is 42%.

4%
Past Growth
42%
Estimated Growth
Estimates Accuracy
-24%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Innate Pharma SA

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
2%
Average Beat

Net Income
Forecast

Net Income Estimate
Innate Pharma SA

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
31%
Average Beat
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is IPH's stock price target?
Price Target
4.995 EUR

According to Wall Street analysts, the average 1-year price target for IPH is 4.995 EUR with a low forecast of 2.414 EUR and a high forecast of 6.51 EUR.

What is Innate Pharma SA's Revenue forecast?
Projected CAGR
42%

For the last 13 years the compound annual growth rate for Innate Pharma SA's revenue is 4%. The projected CAGR for the next 3 years is 42%.

Back to Top